ChemRxiv
These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
ChemrxivEasyChemistryBoström.pdf (600.8 kB)

Can “Easy” Chemistry Produce Complex, Diverse and Novel Molecules?

preprint
submitted on 25.06.2020, 12:58 and posted on 29.06.2020, 07:11 by Anna Tomberg, Jonas Boström

Prompted by reoccurring statements found in the literature, at seminars, and at conferences, regarding the perceived inferiority of “easy-to-make” compounds compared to molecules obtained through other reaction schemes, we have investigated if there are significant differences between these two groups of compounds. As a surrogate for the “easy-to-make” set, we compiled screening compounds made from the most popular chemical reaction in medicinal chemistry, amide bond formation. The other set contained screening compounds made by any other coupling reaction using the expert system for named reaction identification and classification (namerxn) from NextMove Scientific Software. The data sets were rigorously compiled from the AstraZeneca electronic notebooks and screening databases. We can conclude that novelty, diversity and molecular complexity is nowadays not compromised by the use of amide bond formation, mainly due to a steady increase of unique amines made available during the last decades. With this, we can demonstrate that “easy” chemistry allows speedy access to a broad chemical space, facilitating progress in medicinal chemistry projects, and opens the possibility of synthesis automation and new technologies like DNA encoded libraries. That said, we also stress that innovative chemistry must be continuously developed to maintain the production of new elaborate building blocks enabling fast advancement in medicinal chemistry and drug design.

History

Email Address of Submitting Author

jonas.bostrom@astrazeneca.com

Institution

AstraZeneca

Country

Sweden

ORCID For Submitting Author

0000-0002-9719-9137

Declaration of Conflict of Interest

No conflict of interest

Exports